Synthesis of a Novel Compound from Gallic Acid and Linoleic Acid and its Biological Functions

  • Jo, Cheo-Run (Radiation Food Science and Biotechnology Team, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute) ;
  • Jeong, Ill-Yun (Radiation Food Science and Biotechnology Team, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute) ;
  • Lee, Na-Young (Radiation Food Science and Biotechnology Team, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute) ;
  • Kim, Kwan-Soo (Department of Food Science & Nutrition, Chosun University) ;
  • Byun, Myung-Woo (Radiation Food Science and Biotechnology Team, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute)
  • Published : 2006.04.30


Octadeca-9,12-dienyl-3,4,5-hydroxybenzoate (GA-LA) was chemically synthesized from gallic acid and linoleic acid ester, and its biological functions were tested. Radical-scavenging activity of GA-LA was comparable to those of gallic and ascorbic acids at 0.24 mM, and tyrosinase inhibition effect was higher than that of ascorbic acid. Gallic and linoleic acids did not show any tyrosinase activity. Results of cyclooxygenase (COX) inhibition effect indicate GA-LA has higher selectivity in COX-1 inhibition. GA-LA from gallic and linoleic acids could be used as functional reagent for antioxidative, skin-whitening, and anti-inflammatory effects in food, pharmaceutrical, and cosmetic industries.


  1. Soong YY, Barlow PJ. Quantification of gallic acid and ellagic acid from longan (Dimocarpus longan Lour.) seed and mango (Mangifera indica L.) kernel and their effects on antioxidant activity. Food Chem. 97: 524-530 (2006)
  2. Htano T. Constitutents of natural medicines with screening effects on active oxygen species-Tannins and related polyphenols. Nature Medicine 49: 357-363 (1995)
  3. Catterall F, Souquet JM, Cheynier V, de Pascual-Teresa S SantosBuelga C, Clifford MN, Loannides C. Differential modulation of the genotoxicity of food carcinogens by naturally occurring monomeric and dimeric polyphenolics. Environ. Mol. Mutagen 35: 86-98 (2000)<86::AID-EM3>3.0.CO;2-B
  4. Lim MY, Park YH, Som DJ, Kim MK, Lee HS. Antiplatelet activity of gallic acid and methyl gallate. Food Sci. Biotechnol. 13: 806-809 (2004)
  5. Alam A, Takaguchi Y, Ito H, Yoshida T, Tsuboi S. Multi-functionalization of gallic acid towards improved synthesis of $\alpha$ - and ${\beta}-DDB$. Tetrahedron 61: 1909-1918 (2005)
  6. Negi AS, Darokar MP, Chattopadhyay SK, Grag A, Bhattacharya AK, Srivastava V, Khanuja SPS. Synthesis of a novel plant growth promoter from gallic acid. Bioorganic Med. Chem. Lett. 15: 12431247 (2005)
  7. Cho SJ, Tropsha A, Suffuess M, Cheng YC, Lee KH. Structure-based alignment and comparative molecular field analysis of acetylcholineserase inhibitors. J. Med. Chem.39: 1383-1395 (1996)
  8. Yoshmo M, Haneda M, Naruse M, Htay HH, Iwata S, Tsubouchi R, Murakami K. Prooxidant action of gallic acid compound: copperdependent strand breaks and the formation of 8-hydroxy-2'deoxyguanosine in DNA. Toxicol. In Vitro 16: 705-709 (2002)
  9. World Health Organization. Gallates: propyl, octyl, dodecyl. WHO Food Additive Series 32: 3-23 (1993)
  10. Wacher VJ, Benet LZ. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds. US Patent 6180666 B1 (2001)
  11. Zhao G, Etherton TD, Martin KR, Vanden Heuvel JP Gillies PJ West SG, Kris-Etherton P. Anti-inflammatory effects of poiyunsaturatect fatty acids in THP-1 cell. Biochem. Bioph. Res. Co. 336: 909-917 (2005)
  12. Liu CG, Chen XG, Park HJ. Self-assembled nanoparticles based on linoleic-acid modified chitosan: Stability and adsorption of trypsin. Carbohydrate Polym. 62: 293-298 (2005)
  13. Blois MS. Antioxidant activity determination by the use of a stable free radical. Nature 181: 1199-1200 (1958)
  14. Masamoto Y, Iida S, Kubo M. Inhibitory effect of Chinese crude drugs on tyrosinase. Planta Med. 40: 361-365 (1980)
  15. Munas M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W. Resveratrol analogues as selective cycIooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorgan. Med. Chem.12: 5571-5578 (2004)
  16. SAS Institute, Inc. SAS User's Guide. SAS Institute, Inc. Cary, NC. USA (1989)
  17. Halliwell B. Free radicals, antioxidants, and human diseases: curiosity, cause, or consequence? Lancet 334: 721-724 (1994)
  18. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radical Res. 33: S85-S97 (2000)
  19. An BJ, Kwak JH, Son JH, Park JM, Lee JY, Park TS, Kim SY, Kim YS, Jo C, Byun MW, Physiological activity of irradiated green tea polyphenol on the human skin. Am. J. Chinese Med. 33: 353-546 (2005)
  20. Choi BW, Lee BH, Kang KJ, Lee ES, Lee NH. Screening of the tyrosinase inhibitors from marine algae and medicinal plants. Korean J. Pharmacogn. 29: 237-242 (1998)
  21. Kim JA, Lee JM, Shin DB, Lee NH. The antioxidant activity and tyrosinase inhibitory activity of phloro-tannins in Ecklonia cava. Food Sci. Biotechnol. 13: 476-480 (2004)
  22. Weissmann G Prostaglandins as modulators rather than mediators of inflammation. J. Lipid Med. 6: 275-286 (1993)
  23. Raisz LG. Physiologic and pathologic roles of prostagladins and other eicosanoids in bone metabolism. J. Nutr. 125: 2024S-2027S (1995)
  24. Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN. Molecular mechanism of ovulation and luteinization. Mol. Cell Endocrinol. 145: 47-54 (1998)
  25. Rioux N, Castonguay A. The induction of cycIooxygenase-l by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kB. Carcinogenesis 21: 1745-1751 (2000)
  26. Foeldvari I, Burgos-Vargas R, Thon A, Tuerck D. High response rate in the phase IfII study of meloxicarn in juvenile rheumatoid arthritis. Rheumatol. J. 29: 1079-1083 (2002)
  27. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado CJ, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E. Comparison of the effect ofrofecoxib (a cycIooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 43: 370-377 (2000)<370::AID-ANR17>3.0.CO;2-D
  28. Buttar NS, Wang KK. The 'aspirin' of the new millennium: cycleoxygenase 2-inhibitors, Mayo. Clin. Proc. 75: 1027-1038 (2000)
  29. Connolly JM, Liu XH, Rose DP. Dietary linoleic acid-stimulated human breast cancer cell growth and mesastasis in nude mice and their suppression by indomethacin, a cycIooxygenase inhibitor. Nutr. Cancer 25: 231-240 (1996)
  30. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN. CycIooxygenase-1 is up-regulated in cervical carcinomas: autocrinel paracrine regulation of cycIooxygenase-2, prostaglandin e receptors, and angiogenic factors by cycIooxygenase-1. Cancer Res. 62: 424432 (2002)
  31. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cycIo-oxygenase-l rather than cycIooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. P. Natl. Acad. Sci. USA 96: 7563-7568 (1996)